Amendments to the Claims:

Please amend claim 10 as set forth below.

1-9. (Canceled)

10. (Currently amended) A pharmaceutical composition for ophthalmologic uses, comprising a complementary peptide having a sequence complementary to proline-glycine-proline (PGP) (SEQ ID NO:1), wherein said complementary peptide is selected from the group consisting of RTR (SEQ ID NO:2), RTRGG (SEQ ID NO:3), RTR dimer, RTR tetramer, RTR octamer, N-acetyl-RTR multimer, short-chain and long-chain fatty acid RTR multimer, RTR multimer using diaminopropionic acid for the core subunit, RTR multimer using diaminobutyric acid for the core subunit, RTR multimer containing a spacer having the formula ~~$NH_2[CH_2]_n$-COOH[n=2[3-aminopropionic acid]....7[8-aminocaprylic acid]],~~ $NH_2[CH_2]_n$-COOH[n=2[3-aminopropionic acid];3;4;5;6; or 7[8-aminocaprylic acid]], said spacer replacing diglycine spacer, cysteine RTR multimer having a bicyclic structure, and XTR multimer with N-terminal modifications and core subunit modifications, wherein said complementary peptides have dextrorotatory amino acids substituting for the natural levorotatory, and wherein X may be any amino acid.

11. (Previously presented) A method of inhibiting polymorphonuclear leukocyte polarization, chemotaxis, and infiltration into tissue activated by a neutrophil chemoattractant in an individual, comprising the step of administering to said individual a pharmaceutical composition for ophthalmologic uses, so as to inhibit polymorphonuclear leukocyte infiltration into tissue, wherein said neutrophil chemoattractant is selected from the group consisting of N-acetyl-PGP, N-acetyl-PGX, N-

methyl-PGX, N-methyl-PGP, and small peptide chemoattractants containing proline and glycine, wherein said pharmaceutical composition comprises a complementary peptide having a sequence complementary to proline-glycine-proline (PGP) (SEQ ID NO:1), and wherein X may be any amino acid.